Navigation Links
Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV
Date:11/2/2013

ymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations of investigational HCV compounds that work in complementary ways. The recent collaboration of Boehringer Ingelheim with Presidio Pharmaceuticals, Inc. for a Phase 2a clinical study investigating an interferon- and ribavirin-free, all-oral combination is part of the company's continued commitment to discover and develop innovative options for the treatment of HCV.

STARTVerso™ and HCVerso® are registered service marks of Boehringer Ingelheim International GmbH.

The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases (AASLD).

Hepatitis C is a blood-borne infectious disease and a leading cause of chronic liver disease, transplant and failure that affects as many as 150 million people globally. In the United States, approximately 3.2-5.2 million people have chronic HCV infection. Since 1999 there has been a significant increase in deaths due to chronic HCV, which accounts for 10,000-12,000 deaths in the United States per year.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more th
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... India , July 31, 2015 ... CRM solutions for video, data and cloud computing ... with a leading pharma giant for Internet of ... different IoT applications offered on subscription model. ... Pharma giant is striving for business innovations ...
(Date:7/30/2015)... July 30, 2015  ResMed Inc. (NYSE: RMD ... 30, 2015.  Revenue for the quarter was $453.1 million, ... June 30, 2014 (a 17 percent increase on a ... with the quarter ended June 30, 2014.  Diluted earnings ... the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... Denmark , Feb. 1 LEO Pharma ... mebutate) Gel, the company,s lead candidate for the topical treatment ... primary clinical endpoint of complete clearance of AK lesions in ... AK support results from the earlier REGION-I trial, a study ...
... Ill. and CASTRES, France , Feb. 1 ... licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, ... (CIPF) in France and targeting the cMet receptor for ... progression of a range of solid tumors including, prostate, lung and ...
Cached Medicine Technology:LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition 2LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition 3Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer 2Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer 3
(Date:8/1/2015)... NY and Greenwich, CT (PRWEB) , ... August ... ... (“Professional”), a Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier ... Connecticut — incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic ... very first small business donation to kick off the campaign for healing and Well-Being. ... legacy includes a complete line of raw, organic hair care products, as well as ...
(Date:7/31/2015)... Santa Rosa, CA (PRWEB) , ... July 31, ... ... been posted by High Times magazine. What are the STASH awards? The ... celebrate advances made by the cannabis-cultivation community as well as tried-and-true products that ...
(Date:7/31/2015)... ... 2015 , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) ... (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central ... Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, ...
(Date:7/31/2015)... ... ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and black diamond award ... fat reduction in New York. Due to its unparalleled level of experience for ... patients travel to New York to get their non-surgical skin tightening and body shaping ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4
... FORT WORTH, Texas, Nov. 11 Wound Management ... Management Technologies Division will search for partners to ... to develop opportunities within the International Biotechnology and ... developments concerning advisory board appointments, research affiliations, and ...
... FAIRFAX, Va.Catheter-directed therapy or catheter-directed thrombolysisan interventional radiology ... specially designed catheters to dissolve dangerous blood clots ... a first-line treatment option for massive pulmonary embolism, ... Vascular and Interventional Radiology . "Modern ...
... ... announces new research focusing on Employee Engagement, Revenue and the New Economy as kickoff ... ... 12, 2009 -- There is little else more pressing in business than the financial ...
... ... decades The American Red Cross is making available for sale to the ... and bound journals, antique uniforms (1925 – 1941), flags, vintage ... a model train, photographs (including those of the founder Clara Barton, past ...
... The Quigley Corporation, (Nasdaq: QGLY) , ... a conference call in which Ted Karkus, Chairman and CEO, will ... results and Q&A. , The conference call will be ... www.quigleyco.com ), at 11:00 AM (ET) on Thursday, November 12, ...
... , LONDON, Nov. 11 The healthcare market is ... the global economic slowdown. Costs for healthcare are reaching ... exception. Market players in this industry have been faced ... technological advancements in hardware, high replacement costs, exchange rates ...
Cached Medicine News:Health News:OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 2Health News:OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 3Health News:When seconds count: Interventional radiology treatment for pulmonary embolism saves lives 2Health News:When seconds count: Interventional radiology treatment for pulmonary embolism saves lives 3Health News:Performance Connections International Announces New Research Focusing on the Impact of Employee Engagement in the New Economy 2Health News:Performance Connections International Announces New Research Focusing on the Impact of Employee Engagement in the New Economy 3Health News:American Red Cross Auctions Historical Artifacts Through OLS Trading, Inc 2Health News:American Red Cross Auctions Historical Artifacts Through OLS Trading, Inc 3Health News:The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update 2Health News:Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety 2Health News:Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety 3
The SF-3000 automated hematology analyzer can provide accurate and precise 23-parameter hematolgy results including a fully automated WBC 5-part differential from a compact space-save design....
Ac.T 5diff CP allows quick and direct access to a closed sample tubea feature that reduces manual sample handling, saves time and enhances safety by eliminating operators exposure to biohazards....
... 755 simplifies and automates high-volume ... automation and advanced technologies into ... accurate results every time. Plus, ... quality with its slide-on-slide smearing ...
... The CX31 continue ... of the CH2 microscopes ... arenas, now with UIS ... models improve all-around performance ...
Medicine Products: